Related Experiment Videos

Is the use of beta-blockers in COPD still an unresolved dilemma?

Antonio Foresi1, Giampaolo Cavigioli, Giordano Signorelli

  • 1Division of Respiratory Medicine, A.O. Istituti Clinici di Perfezionamento, Sesto San Giovanni Hospital, Viale Matteotti 83, Sesto San Giovanni, Italy. antonio.foresi@icp.mi.it

Respiration; International Review of Thoracic Diseases
|July 20, 2010
PubMed

Insights

Selective beta(1)-blockers are safe for most patients with chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD). Developing standardized protocols can improve beta-blocker use in these patients.

Area of Science:

  • Cardiology
  • Pulmonology
  • Pharmacology

Background:

  • Beta-blockers are crucial for cardiovascular diseases (CVD) and heart failure (HF).
  • Co-prescription of beta-blockers in heart failure patients with chronic obstructive pulmonary disease (COPD) is low (20%) despite guidelines.
  • Pulmonary adverse effects, like bronchoconstriction, limit beta-blocker use in COPD patients.

Purpose of the Study:

  • To investigate the safety and efficacy of selective beta(1)-blockers in patients with both CVD and COPD.
  • To address the underutilization of beta-blockers in heart failure patients with co-existing COPD.
  • To propose strategies for improving beta-blocker prescription in this patient population.

Main Methods:

  • Literature review on beta-blocker pharmacology and clinical use in CVD and COPD.
  • Analysis of factors contributing to underprescription of beta-blockers in heart failure patients with COPD.
  • Discussion of mechanisms of beta-blocker-induced bronchoconstriction and strategies for mitigation.

Main Results:

  • Selective beta(1)-blockers can be safely administered to most COPD patients under controlled conditions.
  • Close monitoring of lung function and individualized dose titration are key to safe administration.
  • Physician mistrust due to concerns about bronchospasm is a primary reason for underuse.

Conclusions:

  • Selective beta(1)-blockers are a viable and safe treatment option for the majority of patients with heart failure and COPD.
  • Standardized protocols developed by pneumologists and cardiologists can enhance physician confidence and improve beta-blocker utilization.
  • Optimizing beta-blocker therapy in CVD patients with COPD can lead to better patient outcomes.

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...